scholarly journals Dual chamber pacemaker in the treatment of paroxysmal atrial fibrillation

2005 ◽  
Vol 62 (4) ◽  
pp. 329-334
Author(s):  
Goran Radjen ◽  
Sasa Rafajlovski ◽  
Zoran Perisic ◽  
Radoslav Romanovic
Keyword(s):  
Atrial Fibrillation ◽  
Paroxysmal Atrial Fibrillation ◽  
Antiarrhythmic Drugs ◽  
Atrial Pacing ◽  
Cardiac Dysrhythmia ◽  
Dual Chamber ◽  
Short Term ◽  
Dual Chamber Pacemaker ◽  
Symptomatic Bradycardia ◽  
High Level

Background. Atrial fibrillation is the most frequent cardiac dysrhythmia. The aim of this study was to show the role and the efficacy of a dual chamber pacemaker with the algorithm of atrial dynamic overdrive, in the suppression of paroxysmal atrial fibrillation. Case report. A woman with a classical bradycardia-tachycardia syndrome, and frequent attacks of atrial fibrillation, underwent the implantation of a single chamber permanent pacemaker (VVI). Pacemaker successfully treated the episodes of symptomatic bradycardia, but the patient had frequent attacks of atrial fibrillation, despite the use of different antiarrhythmic drugs, which she did not tolerate well. The decision was made to reimplant a permanent dual chamber pacemaker with the algorithm of atrial dynamic overdrive. The pacemaker was programmed to the basic rate of 75/min, while rate at rest was 55/min. In addition, sotalol was administered. After three months, the patient became asymptomatic with only 4 short ? term episodes of atrial fibrillation, and a high level of atrial pacing (99%). Conclusion. In selected patients with bradycardia?tachycardia syndrome, atrial-based pacing seemed to be very effective in reducing the incidence of paroxysmal atrial fibrillation.

Increased base rate of atrial pacing for prevention of atrial fibrillation after implantation of a dual-chamber pacemaker: insights from the Atrial Overdrive Pacing Study

EP Europace ◽  
2007 ◽  
Vol 9 (11) ◽  
pp. 1024-1030 ◽  
Author(s):  
B. K. Kantharia ◽  
R. A. Freedman ◽  
D. Hoekenga ◽  
G. Tomassoni ◽  
S. Worley ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Base Rate ◽  
Atrial Pacing ◽  
Dual Chamber ◽  
Dual Chamber Pacemaker ◽  
Overdrive Pacing

scholarly journals The Atrial Pacing Peri-ablation for Paroxysmal Atrial Fibrillation (PA3) Study

EP Europace ◽  
1999 ◽  
Vol 1 (1) ◽  
pp. 40-42 ◽  
Author(s):  
A. M. Gillis
Keyword(s):  
Atrial Fibrillation ◽  
Paroxysmal Atrial Fibrillation ◽  
Time Course ◽  
Primary Study ◽  
Atrial Pacing ◽  
Av Node ◽  
Antiarrhythmic Drug Therapy ◽  
Symptomatic Bradycardia ◽  
First Recurrence ◽  
Outcome Event

Abstract The Canadian Atrial Pacing Peri-Ablation for Paroxysmal Atrial Fibrillation Study tested the hypotheses that atrial pacing prevents paroxysmal atrial fibrillation (PAF) in patients without symptomatic bradycardia and that DDDR pacing is more likely to prevent PAF following total atrioventricular (AV) node ablation compared to VDD pacing. Patients with PAF who were refractory to or intolerant of antiarrhythmic drug therapy received a Medtronic Thera DR pacemaker 3 months prior to a planned total AV node ablation. Patients were randomized to atrial pacing or no pacing therapy. The time to first recurrence of sustained PAF was the primary study outcome event. Following AV node ablation, patients were randomized to the DDDR or VDD mode in a crossover study design. Patients were followed in each mode for 6 months. The time course of PAF recurrence was compared for each pacing mode.

Prevention of long-lasting atrial fibrillation through antitachycardia pacing in 584 dual-chamber pacemaker patients

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
G Boriani ◽  
Y Sakamoto ◽  
S Iacopino ◽  
S Komura ◽  
P Pieragnoli ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Poor Quality ◽  
World Population ◽  
Atrial Pacing ◽  
Dual Chamber ◽  
Antitachycardia Pacing ◽  
Dual Chamber Pacemaker ◽  
Randomized Evaluation ◽  
Low Incidence ◽  
Preventive Atrial Pacing

Abstract Background Atrial fibrillation (AF) is a frequent arrhythmia in pacemaker patients and is associated with poor quality of life and increased risks of heart failure, dementia, stroke, and death. The MINERVA trial has shown that the combination of 3 pacing algorithms – 1) atrial antitachycardia pacing (aATP), 2) atrial preventive pacing and 3) managed ventricular pacing (MVP) - delays progression to persistent and permanent AF, compared with standard DDDR pacing mode and with MVP mode, in pacemaker patients with AF history. Purpose We performed a comparative non randomized evaluation to confirm the hypothesis that aATP is the main driver of persistent/permanent AF reduction independently on the effect of preventive atrial pacing. Methods Thirty-one Italian and Japanese Cardiology centers included consecutive dual-chamber pacemaker patients with AF history. aATP was programmed in all patients while preventive atrial pacing was not enabled. Comparison was made with all the 3 groups in MINERVA randomized trial. The main endpoint was incidence of AF longer than 7 consecutive days, as detected by device diagnostics. Results A total of 146 patients (73 years old, 54% male) were included and followed for a median observation period of 31 months. The 2-year incidence of AF>7 days was 12% in the aATP group, very similar to that found in the arm of the MINERVA trial with aATP enabled (13.8%, p=0.732) and significantly lower than AF incidence found in the MINERVA Control DDDR arm (25.8%, p=0.012) and in the MINERVA MVP arm (25.9%, p=0.025). Conclusions In a real-world population of dual-chamber pacemaker patients with AF history, use of aATP was associated with low incidence of persistent AF during follow up, highlighting that the positive results of the MINERVA trial are related to the effectiveness of aATP rather than to the effects of preventive atrial pacing. Funding Acknowledgement Type of funding source: None

scholarly journals Prospective, randomized study of atrioventricular ablation and mode-switching, dual chamber pacemaker implantation versus medical therapy in drug-resistant paroxysmal atrial fibrillation

EP Europace ◽  
1999 ◽  
Vol 1 (1) ◽  
pp. 15-19 ◽  
Author(s):  
M. Brignole ◽  
L. Gianfranchi ◽  
C. Menozzi ◽  
P. Alboni ◽  
G. Musso ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Drug Therapy ◽  
Paroxysmal Atrial Fibrillation ◽  
Antiarrhythmic Drugs ◽  
Randomized Study ◽  
Pacemaker Implantation ◽  
Mode Switching ◽  
Clinical Effects ◽  
Dual Chamber Pacemaker

Abstract We performed a prospective randomized 6-month evaluation of the clinical effects of atrioventricular junctional ablation together with placement of a DDDR mode-switching pacemaker vs pharmacological treatment in 43 patients with intolerable paroxysmal atrial fibrillation not controlled with antiarrhythmic drugs. Ablation and pacemaker treatment were highly effective and superior to drug therapy in controlling symptoms and improving quality of life. However, discontinuation of drug therapy exposed patients to further recurrences of paroxysmal atrial fibrillation and the risk of developing permanent atrial fibrillation.

scholarly journals Sinus node dysfunction associates with atrial high-rate episodes after DDD pacemaker implantation

2019 ◽  
Author(s):  
Qi Xue ◽  
Hai Zou ◽  
Lihong Wang ◽  
Hong Shao ◽  
Yuan Ma
Keyword(s):  
Atrial Fibrillation ◽  
Sinus Node ◽  
Pacemaker Implantation ◽  
Structural Heart Disease ◽  
Sinus Node Dysfunction ◽  
High Rate ◽  
Atrial Pacing ◽  
Dual Chamber ◽  
Dual Chamber Pacemaker ◽  
Increased Risk

Abstract Background： Patients implanted with pacemakers frequently develop atrial fibrillation. Pacemaker-detected atrial high-rate episodes or AHREs, where one AHRE is defined as ≥ 160beats/min lasting ≥ 5 minutes, may identify patients at increased risk for stroke and death. In this study, we sought to observe whether patients with sinus node dysfunction or atria-ventricular block are more likely to develop AHREs. Methods: A total of 103 patients (age 69.4±13.5 years，58% female) with DDD/DDDR pacemakers were enrolled for the study. These pacemakers were equipped with features that enabled the detection and storage of information such as the dates, durations and sequential episodes of AHRE. Patients were followed up for 2 years and the time of the first occurrence of AHRE was determined at follow-up visit. Other data such as age, gender, structural heart disease, concomitant non-cardiac diseases, the cumulative percentage of atrial pacing (Cum% AP) and ventricular pacing (Cum% VP) were also collected. Results: Atrial fibrillation developed frequently after the dual-chamber pacemaker implantation. AHRE occurred more often in patients with sinus node disease (SND) than those with atrioventricular block (AVB) （OR, 2.553; 95%CI, 1.122-5.814；P=0.045）. Conclusions: AHRE developed frequently after dual-chamber pacemaker implantation. Patients with SND are more likely to develop AF compared to the patients with AVB.

Sign in / Sign up

Export Citation Format

Share Document